出品|远见资本局作者|远见君3月31日,和铂医药发布了2024年度业绩公告。报告期内,和铂医药实现营收3810.0万美元(约合2.74亿元人民币),同比下降57.4%;实现归母净利润277.8万美元(约合1941万元人民币),同比大降87.8%。尽管和铂医药连续2年实现盈利,但是较2023年业绩出现大规模收缩。具体来看,和铂医药的收入分为分子许可费、研究服务费及技术许可费。在2024年业绩公告中,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.